地拉罗司(恩瑞格)治疗铁质积聚的效果如何？

Deferasirox (deferasirox) is an iron chelator product developed by the Swiss pharmaceutical company Novartis. It is the first oral iron chelator approved by the US FDA for routine use. It is approved for use in patients ≥2 years old with chronic iron overload caused by blood transfusion. The application of iron chelators has greatly reduced the mortality and improved the quality of life of patients with long-term blood transfusions, and its clinical application has been receiving widespread attention and attention. So, how effective is deferasirox (Enrige) in treating iron accumulation?

Deferasirox dispersible tablets are an oral active chelating agent that is highly selective for iron (Fe3+). It is a ligand with 3 protrusions that binds iron with high affinity in a 2:1 ratio. Although deferasirox has a very low affinity for zinc and copper, serum concentrations of these trace metals decreased to varying degrees after administration.

The results of a single-arm, multi-center, prospective clinical study enrolling 64 AA patients with transfusion-related iron overload confirmed the effectiveness and safety of Enrig (deferasirox) in reducing patients' ferritin levels. A prospective, observational study in my country using liver, pancreas, and heart as monitoring indicators confirmed that Enrig can improve organ function in patients with iron overload. The results of the TELESTO study released at the ASH 2018 meeting also proved that Enrige continuously reduces serum ferritin levels, while reducing the risk of heart function damage, liver function damage, transformation to leukemia and other events by 36.4%.

(Deferasirox) is easy to administer, significantly reduces ferritin levels, and has a definite effect in protecting important target organ systems such as the liver, heart, and endocrine system. It is currently the preferred option for iron removal treatment.